• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单分子成像对致癌性KRAS动力学进行量化,以提高治疗效果评估的准确性。

Single-molecule imaging quantifies oncogenic KRAS dynamics for enhanced accuracy of therapeutic efficacy assessment.

作者信息

Yokoi Ryoma, Mori Toshiki, Hirosawa Koichiro M, Kondo Ryojiro, Taguchi Tomohiko, Matsuhashi Nobuhisa, Suzuki Kenichi G N

机构信息

Department of Gastroenterological Surgery and Pediatric Surgery, Graduate School of Medicine, Gifu University, Gifu 501-1193, Japan.

Institute for Glyco-Core Research (iGCORE), Gifu University, Gifu 501-1193, Japan.

出版信息

iScience. 2025 Aug 14;28(9):113374. doi: 10.1016/j.isci.2025.113374. eCollection 2025 Sep 19.

DOI:10.1016/j.isci.2025.113374
PMID:40949096
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12424429/
Abstract

Oncogenic KRAS mutations are frequent in colorectal cancer, presenting substantial challenges due to constitutive activation and resistance to molecular-targeted therapies driven by mutation-specific biochemical properties. In this study, using single-molecule imaging, we quantitatively analyzed diffusional behaviors of oncogenic KRAS mutants and associated signaling molecules to elucidate their signaling mechanisms and therapeutic implications. Upon EGF stimulation, KRAS molecules exhibited transient trapping and reduced diffusion due to interactions with SOS1 and BRAF, leading to the temporary formation of signaling complexes. Our results demonstrate that analysis of the temporal fraction and frequency of transient trapping events offers a more sensitive and precise evaluation of KRAS activation levels than western blotting. Furthermore, the study of dynamics of individual oncogenic KRAS molecules provides a more accurate assessment of the therapeutic efficacy of various molecular-targeted drugs. Consequently, we propose a highly sensitive strategy to enhance the therapeutic targeting of oncogenic KRAS in living colorectal cancer cells.

摘要

致癌性KRAS突变在结直肠癌中很常见,由于其组成性激活以及由突变特异性生化特性驱动的对分子靶向治疗的抗性,带来了巨大挑战。在本研究中,我们使用单分子成像技术,定量分析了致癌性KRAS突变体和相关信号分子的扩散行为,以阐明其信号传导机制和治疗意义。在表皮生长因子(EGF)刺激下,KRAS分子由于与SOS1和BRAF相互作用而表现出瞬时捕获和扩散减少,导致信号复合物的临时形成。我们的结果表明,与蛋白质免疫印迹法相比,对瞬时捕获事件的时间分数和频率进行分析,能更灵敏、精确地评估KRAS激活水平。此外,对单个致癌性KRAS分子动力学的研究,能更准确地评估各种分子靶向药物的治疗效果。因此,我们提出了一种高度灵敏的策略,以增强对活的结直肠癌细胞中致癌性KRAS的治疗靶向性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/215a496204bb/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/faa0ea59e051/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/b8fcdadd5d87/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/2718a5a491b5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/73b80c7a4d62/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/863dbc9f019b/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/acd5707a79b9/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/7d074dcd9772/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/6d1a32091337/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/215a496204bb/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/faa0ea59e051/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/b8fcdadd5d87/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/2718a5a491b5/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/73b80c7a4d62/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/863dbc9f019b/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/acd5707a79b9/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/7d074dcd9772/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/6d1a32091337/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0a4/12424429/215a496204bb/gr8.jpg

相似文献

1
Single-molecule imaging quantifies oncogenic KRAS dynamics for enhanced accuracy of therapeutic efficacy assessment.单分子成像对致癌性KRAS动力学进行量化,以提高治疗效果评估的准确性。
iScience. 2025 Aug 14;28(9):113374. doi: 10.1016/j.isci.2025.113374. eCollection 2025 Sep 19.
2
RAS mutation-specific signaling dynamics in response to paralog- and state- selective RAS inhibitors.响应旁系同源物和状态选择性RAS抑制剂的RAS突变特异性信号转导动力学
bioRxiv. 2025 Mar 21:2025.02.14.638317. doi: 10.1101/2025.02.14.638317.
3
Synergy and anti-cooperativity in allostery: Molecular dynamics study of WT and oncogenic KRAS-RGL1.变构中的协同作用和反协同作用:WT 和致癌 KRAS-RGL1 的分子动力学研究。
Proteins. 2024 May;92(5):665-678. doi: 10.1002/prot.26657. Epub 2023 Dec 28.
4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
6
Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDAC.PP2A-B56α 的激活会导致胰腺导管腺癌(PDAC)中表皮生长因子受体(EGFR)信号异常和增殖表型。
bioRxiv. 2025 Jul 31:2025.07.18.665598. doi: 10.1101/2025.07.18.665598.
7
KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.成人转移性结直肠癌肿瘤的KRAS突变检测:一项系统评价与成本效益分析
Health Technol Assess. 2014 Oct;18(62):1-132. doi: 10.3310/hta18620.
8
Literature review of advances and challenges in mutant non-small cell lung cancer.突变型非小细胞肺癌进展与挑战的文献综述
Transl Lung Cancer Res. 2025 Jul 31;14(7):2799-2820. doi: 10.21037/tlcr-2025-164. Epub 2025 Jul 15.
9
ATR expression as a prognostic biomarker in -mutated non-small cell lung cancer.ATR表达作为KRAS突变型非小细胞肺癌的预后生物标志物。 (你提供的原文中“-mutated”这里应该是有个具体基因如“KRAS”等缺失了,我按照补充完整后的意思翻译了,如果不是这样请根据实际情况调整)
J Thorac Dis. 2025 Jul 31;17(7):5197-5209. doi: 10.21037/jtd-2025-1113. Epub 2025 Jul 29.
10
Probing binding and allosteric mechanisms of the KRAS interactions with monobodies and affimer proteins: ensemble-based mutational profiling and thermodynamic analysis of binding energetics and allostery reveal diversity of functional hotspots and cryptic pockets linked by conserved communication network.探究KRAS与单域抗体和亲和体蛋白相互作用的结合及变构机制:基于整体的突变谱分析以及结合能和变构的热力学分析揭示了由保守通讯网络连接的功能热点和隐蔽口袋的多样性。
Phys Chem Chem Phys. 2025 May 28;27(21):11242-11263. doi: 10.1039/d5cp00966a.

本文引用的文献

1
Extracellular vesicles adhere to cells primarily by interactions of integrins and GM1 with laminin.细胞外囊泡主要通过整合素和GM1与层粘连蛋白的相互作用黏附于细胞。
J Cell Biol. 2025 Jun 2;224(6). doi: 10.1083/jcb.202404064. Epub 2025 Apr 30.
2
Uptake of small extracellular vesicles by recipient cells is facilitated by paracrine adhesion signaling.旁分泌黏附信号促进受体细胞对小细胞外囊泡的摄取。
Nat Commun. 2025 Mar 12;16(1):2419. doi: 10.1038/s41467-025-57617-9.
3
A non-toxic equinatoxin-II reveals the dynamics and distribution of sphingomyelin in the cytosolic leaflet of the plasma membrane.
一种无毒的海葵毒素-II 揭示了细胞质单层中鞘磷脂的动态和分布。
Sci Rep. 2024 Jul 23;14(1):16872. doi: 10.1038/s41598-024-67803-2.
4
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.挖掘 KRAS 抑制对肿瘤免疫的治疗意义。
Cancer Cell. 2024 Mar 11;42(3):338-357. doi: 10.1016/j.ccell.2024.02.012.
5
Optimizing Treatment Strategy for Oligometastases/Oligo-Recurrence of Colorectal Cancer.优化结直肠癌寡转移/寡复发的治疗策略
Cancers (Basel). 2023 Dec 27;16(1):142. doi: 10.3390/cancers16010142.
6
StayGold variants for molecular fusion and membrane-targeting applications.StayGold 变体在分子融合和膜靶向应用中的应用。
Nat Methods. 2024 Apr;21(4):648-656. doi: 10.1038/s41592-023-02085-6. Epub 2023 Nov 30.
7
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated G12C.索托拉西布联合帕尼单抗治疗携带 G12C 突变的难治性结直肠癌。
N Engl J Med. 2023 Dec 7;389(23):2125-2139. doi: 10.1056/NEJMoa2308795. Epub 2023 Oct 22.
8
Development of ultrafast camera-based single fluorescent-molecule imaging for cell biology.基于超快相机的单荧光分子成像在细胞生物学中的发展。
J Cell Biol. 2023 Aug 7;222(8). doi: 10.1083/jcb.202110160. Epub 2023 Jun 6.
9
Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS inhibitor efficacy in KRAS-mutated colorectal cancer.反馈激活 EGFR/野生型 RAS 信号轴限制 KRAS 抑制剂在 KRAS 突变型结直肠癌中的疗效。
Oncogene. 2023 May;42(20):1620-1633. doi: 10.1038/s41388-023-02676-9. Epub 2023 Apr 5.
10
Colorectal cancer statistics, 2023.2023 年结直肠癌统计数据。
CA Cancer J Clin. 2023 May-Jun;73(3):233-254. doi: 10.3322/caac.21772. Epub 2023 Mar 1.